ClinicalTrials.gg
Sign In
Status unknownNCT05323669MPTNUpdated Apr 12, 2022

Molecular Profile of Thyroid Nodules

An observational study in Thyroid Cancer and Thyroid Nodule, sponsored by Belarusian State Medical University. Status unknown. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-12.

Primary conditionThyroid NoduleRegistry: Thyroid NeoplasmsReclassifiedWhy we changed it
Registry
Thyroid Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Thyroid Nodule
Why
  1. The study's listed conditions name Thyroid Nodule, a narrower term within Thyroid Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Belarusian State Medical University · Observational

The sponsor has not verified this record recently (last verified Apr 2022), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
400
Ages
18 Years and older
Sex
All
01

Study summary

Profiling and comparative analysis of genomic alterations and miRNA expression in benign and malignant thyroid tumors using histological and cytological specimens will be performed. Obtained information is necessary to create a molecular test to refine the cancer risk of cytologically indeterminate thyroid nodules.

Read the detailed description

This is an non-randomised retrospective study consisting of 2 parts. Part A. Histological specimens (formalin fixed paraffin embedded) of patients who were operated on for benign and malignant thyroid disorders will undergo molecular testing to create a molecular profile of thyroid nodules characteristic of Belarusian population.

Part B. Fixed cytological smears of indeterminate thyroid nodules (categories III, IV and V according to Bethesda scoring system) of operated patients will undergo molecular testing to evaluate the possibility and reliability of molecular testing of fixed cytological smears using available assays.

02

Conditions studied

  • Thyroid Cancer
  • Thyroid Nodule

Browse trials for

Keywords

  • thyroid cancer
  • thyroid nodule
  • miRNA
  • molecular testing
03

In context

Thyroid Nodule Reclassified

207 studies on the registry are indexed under Thyroid Nodule; 64 are open to participants now.

This study's planned enrollment of 400 is above the median of 161 across 82 observational studies indexed under Thyroid Nodule.

Browse Thyroid Nodule studies →

Lead sponsor

Belarusian State Medical University is the lead sponsor of 8 studies on the registry; 1 is open to participants now.

Compared within Thyroid Nodule, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Thyroid Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Population of the Republic of Belarus

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients operated on for malignant and benign thyroid tumors. Age is greater than or equal to 18 years old.

Exclusion criteria

Exclusion Criteria:

no

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
400 participants (estimated)
Patient registry
No
Biospecimen retention
None retained

Interventions

  • Diagnostic testMolecular testing

    Molecular testing of thyroid nodules

06

What researchers measure

Primary outcomes

  1. Molecular profile of thyroid nodules

    To develop a molecular profile of thyroid nodules that will allow to distinguish benign from malignant tumor

    Time frame: 2 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — IPD that underlie results in a publication

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: after summary data are published

Access criteria: IPD will be shared through publications

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2022; primary completion for Dec 2023, 20 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2022
First posted
Apr 12, 2022
StartEst.
Apr 11, 2022
Primary completionEst.
Dec 29, 2023
CompletionEst.
Dec 31, 2024
Last update
Apr 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05323669
Lead sponsor
Belarusian State Medical University
Collaborators
The Institute of Genetics and Cytology National Academy of Sciences of Belarus, Minsk City Clinical Oncologic Centre
Responsible party
Siarhei Yakubouski (MD PhD Assistant Professor, Belarusian State Medical University) — Principal investigator
First posted
Apr 12, 2022
Start date
Apr 11, 2022 (estimated)
Primary completion
Dec 29, 2023 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Apr 12, 2022

Study contacts

Siarhei U Yakubouski, MD PhD
Contact
yakub-2003@yandex.ru
5032186 ext. +37529
Gennadij G Kondratenko, MD PhD Prof
study director · Belarusian State Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Thyroid Nodule →

Other studies from this sponsor

Belarusian State Medical University

Start the discussion